Background & aims: To determine the characteristics of hepatitis C (HCV)- infected patients in 2010 and compare this survey with those reported in 1995 and 2001.Patients and methods: Observational multicentre study conducted in 2010 in French internal medicine, infectious diseases and hepatology departments.Results: A total of 1621 HCV infected...
-
2014 (v1)Journal articleUploaded on: December 4, 2022
-
December 2016 (v1)Journal article
BACKGROUND: Ribavirin exposure after the first dose (D0AUC0-4h) \textgreater1755 mcg.h.L is predictive of sustained virological response (SVR) in patients with hepatitis C treated with peginterferon and ribavirin. The aim of this study was to test the benefit of ribavirin early dose adjustment based on this target in naive patients infected...
Uploaded on: December 4, 2022 -
September 2013 (v1)Journal article
Background & AimsIn phase III trials, the safety profile of triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) seems to be similar in HCV treatment-experienced cirrhotic and non-cirrhotic patients, but few cirrhotics were included. We report the week 16 safety and efficacy analysis in a cohort of compensated...
Uploaded on: February 28, 2023 -
December 2019 (v1)Journal article
Background: Although real-life results of sofosbuvir/simeprevir have been extensively reported from the United States, data from other geographical areas are limited. In the French observational cohort, ANRS CO22 HEPATHER, 9432 patients were given the new oral antivirals from December 2013 to June 30, 2018. We report the results of...
Uploaded on: December 4, 2022 -
July 2014 (v1)Journal article
BACKGROUND & AIMS: We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis. METHODS: In the Compassionate Use of Protease Inhibitors in Viral C Cirrhosis study, 511 patients with HCV genotype 1 infection and...
Uploaded on: March 25, 2023 -
January 2017 (v1)Journal article
Background & aims - We report the first real-life results of the sofosbuvir+daclatasvir combination in hepatitis C virus (HCV) genotype 1 infected patients. Methods - The France REcherche Nord&Sud Sida-hiv Hépatites (ANRS) CO22 HEPATHER "Therapeutic options for hepatitis B and C: A French cohort" is a multicentre observational cohort which...
Uploaded on: February 27, 2023 -
September 2021 (v1)Journal article
BACKGROUND and AIMS: The factors predicting hepatocellular carcinoma (HCC) occurrence in chronic hepatitis B need to be precisely known to improve its detection. We identified pathways and individual predictive factors associated with HCC in the ANRS CO22 HEPATHER cohort. METHODS: The study analyzed HBV-infected patients recruited at 32 French...
Uploaded on: December 4, 2022